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The clinical course of astrocytoma grade 2 (A2) is highly variable and is not reflected by morphological characteristics. Earlier
studies using small series of A2 cases suggest that in situ hybridization (ISH) with chromosome-specific DNA probes allows
for frequent detection of aneusomy 1, trisomy 7, and monosomy 10. The role of trisomy 7 in astrocytoma carcinogenesis is
disputed, however, because of its presence in non-neoplastic brain tissue, as detected by karyotyping. Our objective was to
investigate whether there was a correlation between chromosomal aberrations and survival in a series of 47 cases of A2. All
cases were evaluated for numerical aberrations of chromosomes 1, 7, and 10 by ISH. Chromosomal aberrations were detected
in 68% of cases of A2. Trisomy/polysomy 7 was seen in 31 cases (66%), 22 of which (47%) had a high percentage of this
numerical aberration. Only 11 of these 22 cases also showed aneusomy for 1 or 10. No cells or only a few cells with
aberrations were detected in non-neoplastic control samples. Using Kaplan-Meier analysis, trisomy/polysomy 7 correlated
significantly with shorter survival. Hence, as determined by ISH, trisomy/polysomy 7 is absent in non-neoplastic brain tissue
and is frequently detected in A2, correlating with the malignant progression of the disease. © 2002 Wiley-Liss, Inc.
INTRODUCTION
Genotypic characterization of astrocytoma grade
2 (A2) not only is important in understanding car-
cinogenesis but also might offer prognostic infor-
mation. Such prognostic information may help re-
solve the controversy that exists with regard to the
optimal treatment of A2. So far, only a few studies
have investigated the correlation between cytoge-
netic aberrations and the clinical course of A2
(Kraus et al., 1994; Perry et al., 1997; Sallinen et al.,
1997). Using classic karyotyping, Kimmel and col-
legues (1992) showed that patients with astrocyto-
mas with clonal abnormalities had shorter survival
times compared with patients with astrocytomas
without these abnormalities. Their group of cases
of A2 was too small for separate analysis, however.
The most frequently reported genetic aberra-
tions in A2 include mutation of TP53, loss of het-
erozygosity (LOH) of chromosome arm 17p (von
Deimling et al., 1992), and trisomy 7 (Rey et al.,
1987). A correlation between TP53 mutations and
survival of A2 patients seems unlikely (Kraus et al.,
1994; Al-Sarraj and Bridges, 1995). Previous studies
in small series of A2 cases suggest that in situ
hybridization (ISH) and comparative genomic hy-
bridization (CGH) allow for frequent detection of
chromosomal aberrations, such as gain of chromo-
somes 1 and 7, loss of chromosome 10, and hyper-
diploidy (Table 1). Only two of these investigators
correlated the cytogenetic results with the clinical
course of patients with A2 (Perry et al., 1997; Sal-
linen et al., 1997). Sallinen et al. (1997) suggested
the possible prognostic value of CGH in a series of
11 A2 cases. Perry et al. (1997) concluded that
deletion of chromosome 10 was of prognostic value
when studying the total spectrum of astrocytomas,
while trisomy 7 showed no signiﬁcant correlation
with postoperative survival. The role of trisomy 7
in carcinogenesis of astrocytomas is controversial,
given the fact that this aberration has been de-
tected in cultured, histologically nonmalignant
brain tissues (Heim et al., 1989; Moertel et al.,
1993). In contrast, trisomy 7 has not been detected
by ISH of normal and gliotic brain tissue (Arnoldus
et al., 1992; Dalrymple et al., 1994). The objective
Supported by: Dutch Cancer Society; Nijbakker Morra Founda-
tion.
*Correspondence to: Peter Wessels, M.D., Department of Neu-
rology, University Hospital Maastricht, P.O. Box 5800, 6202 AZ
Maastricht, Netherlands. E-mail: PWES@SNEU.AZM.NL
Received 8 June 2001; Accepted 11 September 2001
Published online 20 December 2001
GENES, CHROMOSOMES & CANCER 33:279–284 (2002)
© 2002 Wiley-Liss, Inc.
DOI 10.1002/gcc.10029
in this study was to reinvestigate the prognostic
value of chromosome 7 aberration in A2. The ISH
technique was applied to routinely processed, par-
afﬁn-embedded biopsy and resection samples, al-
lowing for precise correlation of the genetic consti-
tution of cells with their histologic features.
MATERIALS AND METHODS
Material from Patients
Forty-seven biopsy and resection samples diag-
nosed as supratentorial low-grade diffuse astrocy-
toma or A2 were collected from the ﬁles of the
Departments of Pathology of the University Hos-
pitals of Maastricht and Groningen and the Atrium
Hospital in Heerlen. Astrocytomas diagnosed in
patients under the age of 18 years were excluded.
The samples were revised according to the World
Health Organization (WHO) classiﬁcation (Kleihues
et al., 1993). Overall survival was assessed from the
patients’ records. As controls, 10 samples with non-
neoplastic reactive gliosis were examined (Wessels
et al., 2001). These samples were derived at post-
mortem examination from patients who died from
non-neoplastic neurological causes, that is, brain
infarction (n  5), hemorrhagic infarction (n  1),
traumatic hemorrhage (n  2), and hypoxic en-
cephalopathy (n  2).
ISH Protocol
The most representative parafﬁn blocks were
selected from the 47 A2 cases. Five-micron-thick
sections were cut and pretreated according to a
recently optimized protocol (Hopman and Ra-
maekers, 1998). After deparafﬁnization in xylol and
dehydration in an ethanol series, the tissues were
pretreated in 85% formic acid containing 0.3%
H2O2 for 20 min at room temperature. After dehy-
dration in an acidiﬁed ethanol series, the speci-
mens were incubated at 80°C in 1 M sodium thio-
cyanate. Proteolytic digestion was performed in 4
mg/mL pepsin (from porcine stomach; 2,500–3,500
U per 100 mg protein; Sigma, St. Louis, MO) for 10
min at 37°C in 0.02 M HCl. After dehydration in an
acidiﬁed ethanol series, the tissues were ﬁxed in
1% formaldehyde in phosphate-buffered saline
(PBS) for 15 min, followed by ﬁve subsequent
washing steps in PBS and double-distilled water.
ISH was performed as described earlier (Hop-
man and Ramaekers, 1998). The DNA probes used
were speciﬁc for the heterochromatin (sub-)centro-
mere region of chromosome 1 (1q12, pUC 1.77;
Cooke and Hindley, 1979), the alphoid region of
chromosome 7 (p7t1; Waye et al., 1987), and the
centromere region of chromosome 10 (D10Z1;
Devilee et al., 1988). After denaturation at 80°C for
5 min, hybridization was performed overnight at
37°C under a coverslip in a mixture containing 2
standard saline citrate (SSC), 60% formamide, 10%
dextran sulfate, and 0.2 mg/mL herring sperm
DNA. Post-hybridization washes included two
washes in 2 SSC/0.05%/ Tween at 40°C for 5
min, followed by two washes in 0.1 SSC at 60°C
for 5 min. The biotin-labeled DNA probes were
detected by an immunoperoxidase precipitation re-
action. The slides were incubated for 30 min at
room temperature with mouse-antibiotin monoclo-
nal antibody, followed by biotinylated horse-anti-
mouse immunoglobulin G and then with avidin-
biotin-peroxidase complex (all reagents from
Vector Laboratories, Burlingame, CA). Finally, dia-
TABLE 1. Summary of Results in the Literature of In Situ Hybridization (ISH) and Comparative Genomic Hybridization (CGH)
Studies in Adult Astrocytoma Grade 2 (A2)*
Method and
chromosomes examined
Number of
cases (A2)
Chromosome
aberrations detected Reference
ISH 10, 17 11 10, 17, 17 Campomenosi et al., 1996
ISH 7, 10, X, Y 10 7, 10 Liu et al., 1997
ISH 7, 10, 3 11 7, 10 Perry et al., 1997
ISH 1, 7, 10, 17, X, Y, 1p36 4 7, Aneuploidy Rosso et al., 1997
ISH 7, 10 3 Tetrasomy 7 and 10 Steilen-Gimbel et al., 1996
ISH 1, 2, 7, 1p36 9 1, 1p36, 7, Wernicke et al., 1997
CGH 9 8q Nishizaki et al., 1998
CGH 11
1p, 1pter, 7q, 8q,
10 Sallinen et al., 1997
CGH 10 7, 7q, 8q Schrock et al., 1994
CGH 10
5p, 8q, 12p, 19p,
Xp Weber et al., 1996
*For CGH, the most frequent aberrations are listed.
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minobenzidine (Sigma) in PBS containing 0.03%
H202 was applied for visualization of the peroxidase
activity. To improve identiﬁcation of overlapping
nuclei, we used a novel method that includes ﬂu-
orescent DNA counterstaining with 46-diamino-2-
phenylindole (DAPI; Sigma) and bright-ﬁeld ISH.
Microscopy was performed using a Leica-DMBRE
microscope (Leica Mikroskopie und Systeme
GmbH, Wetzlar, Germany) equipped with a ﬁlter
set for DAPI.
Evaluation of ISH
The number of ISH signals per nucleus was
counted in at least 200 nonoverlapping nuclei, fol-
lowing the criteria proposed by Hopman et al.
(1992). Monosomy was deﬁned as 25% of nuclei
with no signal or one signal per nucleus. Trisomy/
polysomy is deﬁned as 5% of nuclei containing
three or more signals. In accordance with other
studies, 20% of aberrant nuclei was used as the
cutoff for a high-frequency aberration (Campo-
menosi et al., 1996; Perry et al., 1997). The ISH
results were categorized as “normal” (5% aber-
rant nuclei), “low-aberrant” (5–20% aberrant nu-
clei), and “high–aberrant” (20% aberrant nuclei).
The prognostic value of these numerical chromo-
some aberrations was analyzed using log-rank tests
on Kaplan-Meier curves.
RESULTS
Histologic revision of the 47 cases of A2 showed
42 (89%) cases of ﬁbrillary astrocytoma, three (7%)
cases of gemistocytic astrocytoma, and two (4%)
cases of oligo-astrocytomas (all WHO grade 2). For-
ty-ﬁve cases were primary tumors, and two were
recurrences from A2. No patients had been previ-
ously subjected to radiotherapy. Twenty-nine
(62%) patients had undergone stereotactic biopsy,
and in 18 (38%) patients the samples had been
obtained by surgical resection. The follow-up pe-
riod varied from 24 to 200 months. The median
survival interval was 90 months (95% CI: 72–108
months).
Using probes for chromosomes 1, 7, and 10, the
samples with reactive gliosis showed no cells or
only sporadic cells with three ISH signals, and they
were all classiﬁed as normal for all three chromo-
somes (Fig. 1a). Of the cases of A2, 31 (66%)
showed aberrations for one or more of the chromo-
somes investigated (Table 2). The frequency of
cells exhibiting numerical chromosomal aberrations
exceeded 5% in 51% of the cases for chromosome
1, in 66% of the cases for chromosome 7 (Fig. 1b),
and in 53% of the cases for chromosome 10. High-
frequency aberrations with increased copy num-
bers most often were detected for chromosome 7.
In 47% of the samples, the frequency of cells with
aberrations exceeded 20%. A much more limited
number of cases falling into the “high-aberrant”
category were detected with probes for chromo-
somes 1 and 10 (Table 2). The most frequently
detected numerical aberrations of chromosome 7
consisted of trisomies (28 cases), but a few cases
Figure 1. Bright-field microscopy of ISH for chromosome 7 com-
bined with DAPI counterstaining of nuclei. A: A sample of reactive
gliosis with no aberrations for chromosome 7. B: A2 showing many
nuclei with three signals for chromosome 7. Magnification for both A
and B 800.
TABLE 2. Summary of In Situ Hybridization Results in 47
Cases of Astrocytoma Grade 2*
Category
Chromo-
some 1
Chromo-
some 7
Chromo-
some 10
Normala 23 (49%) 16 (34%) 22 (47%)
Low-aberrantb 21 (45%) 9 (19%) 15 (32%)
High-aberrantc 3 (6%) 22 (47%) 10 (21%)
aNormal  5% of cells per case with chromosomal aberrations.
bLow-aberrant  5–20% of cells per case with chromosomal aberra-
tions.
cHigh-aberrant  20% of cells per case with chromosomal aberra-
tions.
*The number (percentage) of cases with numerical chromosomal aber-
rations belonging to the indicated categories is presented.
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showed higher copy numbers (three cases). All nu-
merical aberrations of chromosomes 1 or 10 were
increases in copy numbers, except for two cases
with monosomy 10.
In Figure 2, the individual cases and the corre-
lation between the percentages of aberrant nuclei
for chromosomes 7 and 1 (Fig. 2a) and chromo-
somes 7 and 10 (Fig. 2b) have been depicted. As is
shown, virtually all cases with aberrations of chro-
mosomes 1 or 10 also exhibited high frequencies of
cells with aberrations of chromosome 7. The re-
verse, that is, cases with aberrations of chromosome
7 also showing chromosome 1 and 10 deviations,
holds true only for a limited number of cases. The
results of the Kaplan-Meier analyses are shown in
Figure 3. Trisomy/polysomy 7, according to the
different categories, correlated with shorter sur-
vival (log-rank test: P  0.028). High-frequency
aberrations of chromosome 7 (20% of trisomic/
polysomic cells as cutoff; high-aberrant group) cor-
Figure 2. Scattergram showing the percentages
of aberrant nuclei for chromosome 7 versus chro-
mosome 7 (A) and for chromosome 7 versus chro-
mosome 10 (B) for each of the individual cases of A
2 (n  47).
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related strongly with shorter survival times, com-
pared with A2 with disomy or a low frequency of
aberrations for chromosome 7 (normal and low-
aberrant group taken together; log-rank test: P 
0.008; not shown in Fig. 3). The two tumors with
monosomy 10 were associated with extremely short
survival intervals, that is, 10 and 24 months.
DISCUSSION
The present study shows that numerical aberra-
tions of chromosome 7 occur frequently in A2 and
that their detection by ISH is of prognostic value.
The absence or extremely low frequency of numer-
ical chromosome 7 aberrations in the control sam-
ples with non-neoplastic reactive gliosis is in accor-
dance with the results of earlier ISH studies in
non-neoplastic brain tissue (Arnoldus et al., 1991;
Dalrymple et al., 1994). This may suggest that
trisomy 7, as detected by classic banding analysis in
normal (Heim et al., 1989) and gliotic (Moertel et
al., 1993) brain tissue, most probably is due to
culturing artifacts. Another possible explanation is
that the normal brain tissues in the study of Heim
et al. (1989) contained malignant cells, because
seven of their 11 patients were reported to have
malignant brain tumors. Owing to limitations of the
ISH technique, however, we cannot rule out the
presence of small clones of cells with trisomy 7 in
our gliotic samples.
Our ISH ﬁndings in A2 corroborate results of
previous, smaller series (Table 1). Perry et al.
(1997) described trisomy 7 in half of the A2 cases
they examined. In a double-labeled ISH experi-
ment, Steilen-Gimbel et al. (1996) showed gains of
both chromosomes 7 and 10. CGH studies also
suggest that gain or ampliﬁcation of chromosome 7
and arm 8q, in particular, is typical of A2 (Table 1).
In this study we showed that high-frequency tri-
somy/polysomy of chromosome 7 is strongly corre-
lated with shorter survival times, suggesting clonal
expansion of this cell population during the malig-
nant progression of A2.
Polysomy, in particular trisomy, of chromosome
7 not only is detected frequently in A2 but also is
seen in other preneoplastic and neoplastic lesions.
Trisomy 7 was shown to correlate with poor prog-
nosis in prostate carcinoma (Bandyk et al., 1994).
Furthermore, this aberration is present in the stem-
cell compartment of colon carcinoma and has been
suggested to be involved in the transition of colon
adenoma to carcinoma (Herbergs et al., 1996). Thy-
roid hyperplasia with trisomy 7 is thought to
progress more often to adenoma and carcinoma
(Belge, 1994).
These studies and our present ﬁndings strongly
support the involvement of trisomy/polysomy 7 in
carcinogenesis and tumor progression. We found
no strong indications that trisomy/polysomy 7 is
associated with reactive gliosis and therefore can-
not support the suggestion that this represents a
preneoplastic process (Moertel et al., 1993). Fur-
thermore, the presence of trisomy/polysomy 7 did
not correlate with the age of the patients in the
series of A2 cases described here (unpublished
Figure 3. Survival of patients with A2 classified
on the basis of aberrations of chromosome 7. High
percentages (20%) of aberrant nuclei for chromo-
some 7 correlate most strongly with shorter sur-
vival times (log-rank: P  0.028).
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results), as was suggested for several other types of
solid tumors by Broberg et al. (2001). We conclude
that A2 frequently shows a considerable number of
tumor cells with trisomy/polysomy 7. The detec-
tion of this numerical chromosomal aberration by
ISH may thus be of prognostic value in this type of
brain tumor.
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